GSK Long Term Debt 2010-2022 | GSK

GSK long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
  • GSK long term debt for the quarter ending September 30, 2022 was $22.757B, a 20.41% decline year-over-year.
  • GSK long term debt for 2021 was $28.289B, a 5.95% decline from 2020.
  • GSK long term debt for 2020 was $30.078B, a 0.15% decline from 2019.
  • GSK long term debt for 2019 was $30.122B, a 11.33% increase from 2018.
GSK Annual Long Term Debt
(Millions of US $)
2021 $28,289
2020 $30,078
2019 $30,122
2018 $27,058
2017 $18,383
2016 $19,870
2015 $23,430
2014 $26,108
2013 $24,186
2012 $23,255
2011 $19,578
2010 $22,899
2009 $23,153
GSK Quarterly Long Term Debt
(Millions of US $)
2022-09-30 $22,757
2022-06-30 $23,583
2022-03-31 $39,215
2021-12-31 $28,289
2021-09-30 $28,593
2021-06-30 $28,574
2021-03-31 $31,782
2020-12-31 $30,078
2020-09-30 $30,143
2020-06-30 $31,923
2020-03-31 $31,693
2019-12-31 $30,122
2019-09-30 $30,622
2019-06-30 $29,974
2019-03-31 $30,406
2018-12-31 $27,058
2018-09-30 $32,325
2018-06-30 $33,470
2018-03-31 $19,503
2017-12-31 $18,383
2017-09-30 $18,714
2017-06-30 $15,677
2017-03-31 $18,085
2016-09-30 $20,226
2016-06-30 $21,664
2016-03-31 $22,565
2015-12-31 $23,430
2015-09-30 $23,425
2015-06-30 $22,508
2015-03-31 $23,077
2014-12-31 $26,108
2014-09-30 $22,757
2014-06-30 $24,415
2014-03-31 $25,460
2013-12-31 $24,186
2013-09-30 $24,265
2013-06-30 $25,039
2013-03-31 $26,876
2012-12-31 $23,255
2012-09-30 $21,060
2012-06-30 $21,496
2012-03-31 $18,839
2011-12-31 $19,578
2011-09-30 $22,905
2011-06-30 $23,222
2011-03-31 $23,741
2010-12-31 $22,899
2010-09-30 $23,016
2010-06-30 $22,152
2010-03-31 $23,765
2009-12-31 $23,153
2009-09-30 $24,681
2009-06-30 $20,230
2009-03-31 $21,722
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $69.125B $46.910B
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.477B 10.28
Bio-Rad Laboratories (BIO.B) United States $11.666B 27.68
QIAGEN (QGEN) Netherlands $11.120B 18.98
Ginkgo Bioworks Holdings (DNA) United States $3.552B 0.00
Myovant Sciences (MYOV) United Kingdom $2.592B 0.00
Arcus Biosciences (RCUS) United States $1.934B 29.03
Biohaven (BHVN) United States $1.080B 0.00
Emergent Biosolutions (EBS) United States $0.594B 4.67
Zymeworks (ZYME) Canada $0.494B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.276B 0.00
Enzo Biochem (ENZ) United States $0.095B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00